Neutralizing monoclonal antibodies for treatment of COVID-19 by Taylor, PC, Adams, AC, Hufford, MM, De La Torre, I, Winthrop, K, Gottlieb, RL

Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated d... by Taylor, P, Takeuchi, T, Burmester, GR, Durez, P, Smolen, JS, Deberdt, W, Issa, M, Terres, JR, Bello, N, Winthrop, K

Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 9.3 years: an updated integrated safety analysis by Taylor, P, Takeuchi, T, Burmester, G, Durez, P, Smolen, J, Deberdt, W, Zhong, J, Teres, JR, Bello, N, Winthrop, K, Pope, J